top
Please input keywords
Order
*Country
日本
アメリカ
中国
オーストラリア
シンガポール
イギリス
フランス
ドイツ
スイス
イタリア
カナダ
韓国
オランダ
ベルギー
スウェーデン
その他
*Province
*City
*Name
*Telephone
*Company
*Position
*Email
*Verification code
*Verification Code
B-hEPCAM LLC1
Common name
B-hEPCAM LLC1 Catalog number   322009
Aliases

DIAR5, EGP-2, EGP40, ESA,

HNPCC8,  TROP1

Disease  Lewis lung carcinoma
Organism
Mouse 
Strain  C57BL/6
Tissue types Lung Tissue  Lung
Description 

The mouse Epcam gene was replaced by human EPCAM coding sequence in B-hEPCAM LLC1 cells. Human EPCAM is highly expressed on the surface of B-hEPCAM LLC1 cells.

Application

B-hEPCAM LLC1 cells have the capability to establish tumors in vivo and can be used for efficacy studies.

Targeting strategy

Gene targeting strategy for B-hEPCAM LLC1 cells. The exogenous promoter and human EPCAM coding sequence was inserted to replace part of murine exon 4 and all of exons 5~7. The insertion disrupts the endogenous murine Epcam gene, resulting in a non-functional transcript.

Protein expression analysis 

from clipboard

EPCAM expression analysis in B-hEPCAM LLC1 cells by flow cytometry. Single cell suspensions from wild-type LLC1 and B-hEPCAM LLC1 cultures were stained with species-specific anti-EPCAM antibody. Human EPCAM was detected on the surface of B-hEPCAM LLC1 cells but not wild-type LLC1 cells. The 1-B12 clone of B-hEPCAM LLC1 cells were used for in vivo experiments.


Tumor growth curve & Body weight changes

from clipboard

Subcutaneous homograft tumor growth of B-hEPCAM LLC1 cells. B-hEPCAM LLC1 cells (2x105) were subcutaneously implanted into C57BL/6 mice (female, 11-week-old, n=6). Tumor volume and body weight were measured thrice a week. (A) Average tumor volume ± SEM. (B)  Body weight (Mean± SEM). Volume was expressed in mm3 using the formula: V=0.5 X long diameter X short diameter2. As shown in panel A, B-hEPCAM LLC1 cells were able to establish tumors in vivo and can be used for efficacy studies.

Protein expression analysis of tumor cells

from clipboard

B-hEPCAM LLC1 cells were subcutaneously transplanted into C57BL/6 mice (n=6). At the end of the experiment, tumor cells were harvested and assessed for human EPCAM expression by flow cytometry. As shown, human EPCAM was highly expressed on the surface of tumor cells. Therefore, B-hEPCAM LLC1 cells can be used for in vivo efficacy studies of novel EPCAM therapeutics.